A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities

NCT03410927 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class

Stopped The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2

Conditions

Interventions

Sponsor

Taiho Oncology, Inc.